Cargando…

Chemiluminescence-initiated and in situ-enhanced photoisomerization for tissue-depth-independent photo-controlled drug release

Tissue-penetration-depth-independent self-luminescence is highly expected to perform photoisomerization-related bioapplications in vivo to overcome the limitation of shallow tissue-penetration from external photoexcitation. However, it remains extremely challenging because of lacking a target-specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yufu, Lu, Xiaomei, Yin, Chao, Zhao, Hui, Hu, Wenbo, Hu, Xiaoming, Li, Yuanyuan, Yang, Zhen, Lu, Feng, Fan, Quli, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354828/
https://www.ncbi.nlm.nih.gov/pubmed/30809357
http://dx.doi.org/10.1039/c8sc04012e
Descripción
Sumario:Tissue-penetration-depth-independent self-luminescence is highly expected to perform photoisomerization-related bioapplications in vivo to overcome the limitation of shallow tissue-penetration from external photoexcitation. However, it remains extremely challenging because of lacking a target-specific high-intensity self-luminescence to precisely and effectively drive the photoisomerization. Here, we first report a target-specific tissue-depth-independent photoisomerization in vivo by developing a target-specific initiated and in situ-enhanced chemiluminescence (one of self-luminescence) strategy that overcomes the limitation of lacking target-specific high-intensity self-luminescence. Considering that photoisomerization shows boundless glamour in drug-controlled release for disease-specific chemotherapy, we demonstrated applicability of our strategy to apply it in tumor-specific self-luminescence-controlled drug chemotherapy. Specifically, a chemiluminescence substrate and chemiluminescence fluorophore (antitumor drug, CPT) were co-encapsulated in host–guest carriers composed of cyclodextrin and the photoisomerization molecule azobenzene. Tumor-specific H(2)O(2)-induced chemiluminescence preliminarily isomerizes azobenzene, triggering the partial dissociation of host–guest carriers and CPT release. Particularly, the initially released CPT again functions as a chemiluminescence enhancer to achieve in situ enhanced chemiluminescence, assuring target-specific enhanced isomerization and CPT release. With high tumor-inhibition-rate (73%) and no obvious therapy-side-effect in vivo indicates the good efficiency and target-specificity of our chemiluminescence-driven photoisomerization. Although we only demonstrated one example of a photoisomerization-related bioapplication, namely photoisomerization-controlled drug chemotherapy, our work provides guidelines to design various target-specific tissue-depth-independent photoisomerization for bioapplications.